Yes, not sure about the technicalities involved but in theory I presume the addition of lactase could be a potential solution. Just how effective it would be, and how much it would cost, I don't know, and natural A2 milk would always be preferable to consumers rather than A1 milk with a label saying "contains lactase to make it safer for consumption" or words to that effect. Obviously a2MC would be aware of this potential solution, and I wouldn't be surprised if it has IP designed to inhibit its use
Another theoretical approach might involve the use of an enzyme, DPP4, which naturally breaks down BCM7 in healthy consumers and prevents it passing through the gut wall from the gastro-intestinal tract into the bloodstream where it becomes dangerous. It is attached to the epithelial cells in the GI system, but if the gut lining is compromised (which occurs in a significant number of diseases and conditions) the BCM7 is able to penetrate the gut wall and even pass through the blood/brain barrier. I have no idea whether it would be possible to synthesise and insert DPP4 into milk prior to consumption in such a way as to neutralise BCM7, but presumably some clever scientists are looking at this.
The role of DPP4 is dealt with briefly in Keith Woodford"s book (2nd edition), which explains pretty clearly why most people are able to drink A1 milk without problems, but those with "leaky gut" or who have been on antibiotics are at risk from a range of conditions such as coeliac disease and type 1 diabetes if they consume A1 protein. This is important because the question is often asked, why do a majority of consumers tolerate milk containing the A1 protein while a minority do not? And it points to the concerning impication that with the use of antibiotics becoming more and more common, the risks arising from A1 will be increasing year by year.
- Forums
- ASX - By Stock
- A2M
- A2M 17th $2 +
A2M 17th $2 +, page-290
-
- There are more pages in this discussion • 303 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
(20min delay)
|
|||||
Last
$5.91 |
Change
0.010(0.17%) |
Mkt cap ! $4.278B |
Open | High | Low | Value | Volume |
$6.03 | $6.07 | $5.90 | $11.65M | 1.965M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5500 | $5.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.91 | 2504 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 11972 | 5.890 |
2 | 31393 | 5.880 |
2 | 12054 | 5.870 |
2 | 9980 | 5.860 |
3 | 1150 | 5.850 |
Price($) | Vol. | No. |
---|---|---|
5.910 | 2504 | 1 |
5.920 | 8176 | 2 |
5.940 | 4146 | 1 |
5.960 | 12222 | 4 |
5.970 | 24200 | 5 |
Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online